5.59
-0.06(-1.06%)
Currency In USD
| Previous Close | 5.65 |
| Open | 5.64 |
| Day High | 5.65 |
| Day Low | 5.42 |
| 52-Week High | 6.78 |
| 52-Week Low | 3.21 |
| Volume | 2.7M |
| Average Volume | 3.69M |
| Market Cap | 1.34B |
| PE | -24.3 |
| EPS | -0.23 |
| Moving Average 50 Days | 5.71 |
| Moving Average 200 Days | 5 |
| Change | -0.06 |
If you invested $1000 in Ardelyx, Inc. (ARDX) 10 years ago, it would be worth $1,169.46 as of November 08, 2025 at a share price of $5.59. Whereas If you bought $1000 worth of Ardelyx, Inc. (ARDX) shares 5 years ago, it would be worth $3,964.54 as of November 08, 2025 at a share price of $5.59.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
GlobeNewswire Inc.
Yesterday at 9:05 PM GMT
WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
GlobeNewswire Inc.
Nov 05, 2025 1:00 PM GMT
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs
Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
GlobeNewswire Inc.
Nov 04, 2025 1:00 PM GMT
WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs